Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report

    loading  Checking for direct PDF access through Ovid

Abstract

Rationale:

Developing an optimal medication strategy poses a challenging task in fragile patients after left atrial appendage closure (LAAC). We report an optimal nonvitamin K antagonist oral anticoagulant (NOAC) therapy in a warfarin-sensitive patient after LAAC.

Patient concerns:

A 77-year-old nonvalvular atrial fibrillation (NVAF) male carrying 2 warfarin-sensitive alleles experienced 2 gum-bleeding with the international normalized ratio (INR) around 3.

Diagnoses:

Persistent NVAF with a history of subtotal gastrectomy and moderate renal insufficiency.

Interventions:

Warfarin was discontinued and vitamin K1 was immediately administrated via intravenous infusion. LAAC was regarded as a preferable option, and rivaroxaban 15 mg daily was managed after LACC.

Outcomes:

Complete endothelialization on the surface of device was detected via transoesophageal echocardiography (TEE), and no peridevice spillage and adverse event occurred.

Lessons:

A post-LAAC treatment with NOAC may be a viable regimen in patients intolerant to warfarin.

Related Topics

    loading  Loading Related Articles